BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 26, 2021
Distillery Therapeutics

FOXI1, CAII inhibition to treat tuberous sclerosis complex-associated kidney cysts

DISEASE CATEGORY: Renal
INDICATION: Renal damage Targeting transcription factor FOXI1 or downstream target CAII, a cytoplasmic carbonic anhydrase, could treat kidney cysts associated with tuberous
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases
BioCentury | Apr 18, 2018
Distillery Techniques

Disease models

BioCentury | Dec 13, 2016
Distillery Therapeutics

Cancer

BioCentury | Mar 27, 2014
Strategy

Explaining the exceptions

BioCentury | Dec 13, 2012
Cover Story

Translating autism

BioCentury | Sep 6, 2012
Distillery Therapeutics

Indication: Cancer

BioCentury | Mar 24, 2011
Distillery Techniques

Technology: Disease models

BioCentury | Dec 4, 2008
Cover Story

New strategies for CNS regeneration

Items per page:
1 - 10 of 13
Help Center
Username
Request a Demo
Request Training
Ask a Question